EMA-话题@MedSci

#EMA#

580篇内容 | 2489人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1317614, encodeId=78b3131e614e4, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=欧洲药品管理局（EMA）授予ARU-1801治疗镰状细胞病的优先药品资格（PRIME）, objectType=article, longId=206793, objectId=2ade206e932f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ade206e932f, replyNumber=0, likeNumber=74, createdTime=2021-02-06, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ade206e932f, moduleTitle=欧洲药品管理局（EMA）授予ARU-1801治疗镰状细胞病的优先药品资格（PRIME）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ade206e932f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317613, encodeId=cecb131e61344, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=欧洲药品管理局（EMA）开始审查GBT的镰状细胞疗法Oxbryta, objectType=article, longId=206442, objectId=8d542064424c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d542064424c, replyNumber=0, likeNumber=65, createdTime=2021-02-01, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d542064424c, moduleTitle=欧洲药品管理局（EMA）开始审查GBT的镰状细胞疗法Oxbryta, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d542064424c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317612, encodeId=9749131e612e6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤, objectType=article, longId=206006, objectId=dea22060068e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dea22060068e, replyNumber=0, likeNumber=60, createdTime=2021-01-23, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dea22060068e, moduleTitle=Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dea22060068e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317611, encodeId=4636131e6118e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：3期| 套细胞淋巴瘤自体造血干细胞移植后采用来那度胺维持治疗, objectType=article, longId=206002, objectId=eebf206002c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eebf206002c2, replyNumber=0, likeNumber=78, createdTime=2021-01-23, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eebf206002c2, moduleTitle=Lancet Haematol：3期| 套细胞淋巴瘤自体造血干细胞移植后采用来那度胺维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eebf206002c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317610, encodeId=4ae9131e61083, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Br J Haematol：一例晚期霍奇金淋巴瘤患者感染新冠病毒后，肿瘤竟然消失了, objectType=article, longId=205598, objectId=b6fa205598d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6fa205598d9, replyNumber=0, likeNumber=87, createdTime=2021-01-12, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6fa205598d9, moduleTitle=Br J Haematol：一例晚期霍奇金淋巴瘤患者感染新冠病毒后，肿瘤竟然消失了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6fa205598d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317609, encodeId=7a88131e609e1, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Br J Haematol :万万想不到，一名霍奇金淋巴瘤患者感染SARS-CoV-2后体内肿瘤竟然消退了, objectType=article, longId=205496, objectId=7e5b205496bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e5b205496bc, replyNumber=0, likeNumber=91, createdTime=2021-01-10, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e5b205496bc, moduleTitle=Br J Haematol :万万想不到，一名霍奇金淋巴瘤患者感染SARS-CoV-2后体内肿瘤竟然消退了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e5b205496bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317608, encodeId=0a23131e60853, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=安进公司向EMA提交KRAS抑制剂sotorasib治疗非小细胞肺癌的上市申请, objectType=article, longId=204984, objectId=f80e2049842c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f80e2049842c, replyNumber=0, likeNumber=75, createdTime=2020-12-31, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f80e2049842c, moduleTitle=安进公司向EMA提交KRAS抑制剂sotorasib治疗非小细胞肺癌的上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f80e2049842c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317607, encodeId=85d1131e607b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=诺和诺德（Novo Nordisk）寻求欧盟批准Semaglutide治疗肥胖症, objectType=article, longId=204717, objectId=96c0204e17aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96c0204e17aa, replyNumber=0, likeNumber=68, createdTime=2020-12-22, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96c0204e17aa, moduleTitle=诺和诺德（Novo Nordisk）寻求欧盟批准Semaglutide治疗肥胖症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96c0204e17aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317606, encodeId=3802131e60661, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet haematol：达比加群酯有望替代静脉血栓栓塞儿童患者的标准治疗？, objectType=article, longId=204571, objectId=a2732045e132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2732045e132, replyNumber=0, likeNumber=50, createdTime=2020-12-17, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2732045e132, moduleTitle=Lancet haematol：达比加群酯有望替代静脉血栓栓塞儿童患者的标准治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2732045e132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317605, encodeId=f4a1131e60537, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=ASCO-GI 2020：Bemarituzumab的II期FIGHT试验取得积极结果, objectType=article, longId=204372, objectId=c6472043e202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6472043e202, replyNumber=0, likeNumber=70, createdTime=2020-12-12, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6472043e202, moduleTitle=ASCO-GI 2020：Bemarituzumab的II期FIGHT试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6472043e202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317604, encodeId=40f5131e6049e, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Br J Haematol：来那度胺治疗失败后，复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗, objectType=article, longId=204234, objectId=b3d02042345e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3d02042345e, replyNumber=0, likeNumber=90, createdTime=2020-12-08, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3d02042345e, moduleTitle=Br J Haematol：来那度胺治疗失败后，复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3d02042345e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317603, encodeId=8627131e603dd, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=EMA授予泡泡男孩病两项基因治疗药物的孤儿药资格, objectType=article, longId=204054, objectId=9c21204054f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c21204054f5, replyNumber=0, likeNumber=85, createdTime=2020-12-04, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c21204054f5, moduleTitle=EMA授予泡泡男孩病两项基因治疗药物的孤儿药资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c21204054f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317602, encodeId=19a7131e602f2, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍, objectType=article, longId=203477, objectId=04852034e7dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04852034e7dd, replyNumber=0, likeNumber=89, createdTime=2020-11-18, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04852034e7dd, moduleTitle=全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04852034e7dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317601, encodeId=e246131e6013c, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=因肝衰竭风险，EMA进一步限制子宫肌瘤药物Esmya的适用患者范围, objectType=article, longId=203470, objectId=f1012034e0d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1012034e0d9, replyNumber=0, likeNumber=80, createdTime=2020-11-18, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1012034e0d9, moduleTitle=因肝衰竭风险，EMA进一步限制子宫肌瘤药物Esmya的适用患者范围, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1012034e0d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317600, encodeId=3dcc131e60001, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Clin Cancer Res：HR+HER2-脑转移乳腺癌患者从Abemaciclib治疗中获益很大, objectType=article, longId=202711, objectId=dfca202e11b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfca202e11b8, replyNumber=0, likeNumber=83, createdTime=2020-11-02, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfca202e11b8, moduleTitle=Clin Cancer Res：HR+HER2-脑转移乳腺癌患者从Abemaciclib治疗中获益很大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfca202e11b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317599, encodeId=1dce131e59964, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=ESID 2020：敏感性分析证实了Emapalumab治疗噬血细胞性淋巴组织细胞增多症（HLH）的功效, objectType=article, longId=202282, objectId=8ace202282a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ace202282a7, replyNumber=0, likeNumber=72, createdTime=2020-10-21, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ace202282a7, moduleTitle=ESID 2020：敏感性分析证实了Emapalumab治疗噬血细胞性淋巴组织细胞增多症（HLH）的功效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ace202282a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317598, encodeId=727a131e59843, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Ann Hematol：异基因干细胞移植可有效治疗DLBCL, objectType=article, longId=201788, objectId=4e94201e8841, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e94201e8841, replyNumber=0, likeNumber=65, createdTime=2020-10-08, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e94201e8841, moduleTitle=Ann Hematol：异基因干细胞移植可有效治疗DLBCL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e94201e8841)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317597, encodeId=6dff131e597dd, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Am J Hematol：异基因造血干细胞移植治疗前的调理治疗, objectType=article, longId=201785, objectId=f030201e8519, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f030201e8519, replyNumber=0, likeNumber=85, createdTime=2020-10-08, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f030201e8519, moduleTitle=Am J Hematol：异基因造血干细胞移植治疗前的调理治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f030201e8519)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317596, encodeId=7196131e59694, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Hematology：同种异体造血干细胞移植严重和非严重疲劳受者肺和肺外特征的差异, objectType=article, longId=201784, objectId=b56a201e8489, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b56a201e8489, replyNumber=0, likeNumber=65, createdTime=2020-10-08, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b56a201e8489, moduleTitle=Hematology：同种异体造血干细胞移植严重和非严重疲劳受者肺和肺外特征的差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b56a201e8489)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317595, encodeId=a3b2131e59509, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Ann Hematol：每日两次VS隔天口服铁剂治疗缺铁性贫血的疗效, objectType=article, longId=201698, objectId=03462016982b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03462016982b, replyNumber=0, likeNumber=78, createdTime=2020-10-06, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03462016982b, moduleTitle=Ann Hematol：每日两次VS隔天口服铁剂治疗缺铁性贫血的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03462016982b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

EMA

2020-05-29

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

欧洲药品管理局（EMA）授予ARU-1801治疗镰状细胞病的优先药品资格（PRIME）

2021-02-06

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

欧洲药品管理局（EMA）开始审查GBT的镰状细胞疗法Oxbryta

2021-02-01

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤

2021-01-23

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：3期| 套细胞淋巴瘤自体造血干细胞移植后采用来那度胺维持治疗

2021-01-23

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Br J Haematol：一例晚期霍奇金淋巴瘤患者感染新冠病毒后，肿瘤竟然消失了

2021-01-12

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Br J Haematol :万万想不到，一名霍奇金淋巴瘤患者感染SARS-CoV-2后体内肿瘤竟然消退了

2021-01-10

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

安进公司向EMA提交KRAS抑制剂sotorasib治疗非小细胞肺癌的上市申请

2020-12-31

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

诺和诺德（Novo Nordisk）寻求欧盟批准Semaglutide治疗肥胖症

2020-12-22

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet haematol：达比加群酯有望替代静脉血栓栓塞儿童患者的标准治疗？

2020-12-17

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

ASCO-GI 2020：Bemarituzumab的II期FIGHT试验取得积极结果

2020-12-12

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Br J Haematol：来那度胺治疗失败后，复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗

2020-12-08

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

EMA授予泡泡男孩病两项基因治疗药物的孤儿药资格

2020-12-04

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

全球**纳米抗体Caplacizumab继FDA、EMA之后，再次获得NICE批准治疗罕见病患者的凝血障碍

2020-11-18

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

因肝衰竭风险，EMA进一步限制子宫肌瘤药物Esmya的适用患者范围

2020-11-18

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Clin Cancer Res：HR+HER2-脑转移乳腺癌患者从Abemaciclib治疗中获益很大

2020-11-02

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

ESID 2020：敏感性分析证实了Emapalumab治疗噬血细胞性淋巴组织细胞增多症（HLH）的功效

2020-10-21

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Ann Hematol：异基因干细胞移植可有效治疗DLBCL

2020-10-08

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Am J Hematol：异基因造血干细胞移植治疗前的调理治疗

2020-10-08

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Hematology：同种异体造血干细胞移植严重和非严重疲劳受者肺和肺外特征的差异

2020-10-08

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Ann Hematol：每日两次VS隔天口服铁剂治疗缺铁性贫血的疗效

2020-10-06

科室
- - 订阅+
  - 更多科室
工具
服务